EGFR and colorectal carcinoma: Since oncogenic mutations in genes encoding key downstream effectors within EGFR-signaling pathway are responsible for primary intrinsic resistance and reduced efficacy of EGFR-mAbs [33], further understanding of key components of the EGFR-signaling pathway that are frequently altered in metastatic CRC has resulted in a significant step towards improving patient selection and outcome.